首頁 > 市場調查報告書 > 醫療設備

整形外科

市場調查報告書

商品編碼

1624999

2024 年至 2031 年黏彈性補充劑市場規模（按產品類型、材料類型、應用、最終用戶、分銷管道和地區劃分）

Viscosupplementation Market Size by Product Type, Material Type, Application, End-User, Distribution Channel & Region for 2024-2031

出版日期: 2024年11月03日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

黏液補充市場評估，2024-2031 年

由於骨關節炎和其他關節疾病的發生率不斷上升，黏彈性補充劑市場正在擴大。隨著醫療保健提供者擴大採用這些治療方法來緩解疼痛和改善關節功能，基於透明質酸的產品的創新正在推動需求。因此，預計 2024 年市場規模將超過 65 億美元，到 2031 年將達到約 123.8 億美元。

此外，隨著老齡化人口的擴大，對手術以外治療選擇的需求也日益增長。此外，黏彈性補充療法作為一種微創治療方法越來越受到尋求替代傳統關節手術的患者歡迎。由於關節內置換治療的需求不斷增長，預計 2024 年至 2031 年期間市場複合年增長率為 9.24%。

定義/概述

黏彈性補充療法是一種將透明質酸注入關節以增加潤滑和緩衝的治療方法。它主要用於控制骨關節炎患者的疼痛和改善其活動能力。

它主要用於透過增加滑液來緩解關節疼痛，尤其是膝蓋疼痛。這種非手術治療方法在治療中度關節炎方面越來越受歡迎，並被廣泛採用。

未來前景包括透明質酸配方的不斷進步，從而帶來更好的效果。人口老化和對非侵入性治療的需求不斷增長，促進了黏液補充市場的潛在擴張。

範例下載

骨關節炎盛行率的不斷上升如何推動黏彈性補充劑市場的成長？

骨關節炎盛行率的不斷上升對有效的疼痛管理解決方案產生了更高的需求，從而極大地推動了黏彈性補充劑市場的成長。隨著越來越多的人尋求緩解關節疼痛和提高活動能力，醫療保健提供者擴大採用黏液補充療法。這種微創選擇為手術介入提供了可行的替代方案，並將吸引尋求有效但微創方法的患者。因此，這一趨勢正在支持整個市場的擴張。

黏液補充療法的高成本會阻礙市場成長嗎？

黏液補充療法的高成本限制了許多患者能夠接受該療法，對市場的成長構成了重大課題。保險覆蓋範圍的差異進一步加劇了這個問題，因為並非所有保險計劃都提供足夠的報銷。因此，患者可以選擇更實惠的替代療法，從而減少對黏液補充的需求。這些經濟障礙將阻礙醫療保健提供者的採用，並最終影響黏液補充市場的整體成長和潛力。

The Viscosupplementation Market is increasing due to the rising prevalence of osteoarthritis and other joint disorders. Innovations in hyaluronic acid-based products are driving demand, with healthcare providers increasingly adopting these treatments for pain relief and joint function improvement. This is likely to enable the market size to surpass USD 6.5 Billion valued in 2024 to reach a valuation of aroundUSD 12.38 Billion by 2031.

Additionally, the market is seeing growth from the expanding aging population, which is driving the need for non-surgical options. Moreover, increasing awareness about viscosupplementation as a minimally invasive treatment is contributing to its popularity among patients seeking alternatives to traditional joint surgeries. The rising demand for viscosupplementation is enabling the market to grow at aCAGR of 9.24% from 2024 to 2031.

Definition/Overview

Viscosupplementation is a medical treatment involving hyaluronic acid injections into joints, increasing lubrication and cushioning. It is primarily used to manage pain and improve mobility in osteoarthritis patients.

Its use is focused on alleviating joint pain, particularly in the knee, by increasing synovial fluid. This non-surgical option is increasingly popular for managing moderate arthritis cases, driving adoption.

Future scope includes increasing advancements in hyaluronic acid formulations, driving better outcomes. The aging population and increasing demand for non-invasive treatments are contributing to the expanding market potential for viscosupplementation.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How Is the Increasing Prevalence of Osteoarthritis Driving the Growth Of The Viscosupplementation Market?

The increasing prevalence of osteoarthritis significantly drives the growth of the Viscosupplementation market by creating a higher demand for effective pain management solutions. As more individuals seek relief from joint pain and improved mobility, healthcare providers increasingly adopt viscosupplementation treatments. These minimally invasive options offer a viable alternative to surgical interventions, appealing to patients looking for effective yet less invasive approaches. Consequently, this trend supports the expansion of the market overall.

How Does the High Cost of Viscosupplementation Treatments Challenge the Growth of The Market?

The high cost of Viscosupplementation treatments poses a significant challenge to market growth by limiting accessibility for many patients. Insurance coverage discrepancies further exacerbate this issue, as not all plans provide adequate reimbursement. Consequently, patients may opt for alternative, more affordable treatments, reducing demand for viscosupplementation. This financial barrier can hinder widespread adoption among healthcare providers, ultimately impacting the overall expansion and potential of the viscosupplementation market.

Category-wise Acumens

How Will the Increasing Effectiveness of Hyaluronic Acid in Pain Management Drive the Growth of The Hyaluronic Acid-Based Product Segment?

The increasing effectiveness of hyaluronic acid in pain management will drive the growth of the hyaluronic acid-based product segment in the Viscosupplementation Market. Its ability to improve joint lubrication and mobility, particularly in osteoarthritis patients, makes it a preferred treatment option. As more healthcare providers and patients recognize its benefits in offering long-lasting relief without surgery, demand for hyaluronic acid-based products will continue to expand, supporting this segment's growth.

How Will the Growing Preference for Minimally Invasive Procedures Drive the Growth Of The Single Injection Segment?

The growing preference for minimally invasive procedures will drive the growth of the single injection segment in the Viscosupplementation Market. Single injections offer a simpler, less invasive option for osteoarthritis patients, reducing the number of hospital visits and overall discomfort. This convenience appeals to both patients and healthcare providers, enhancing its adoption. As the demand for efficient and patient-friendly treatments increases, the single injection segment is positioned for significant growth.

Country/Region-wise Acumens

Will The High Prevalence of Osteoarthritis and Advanced Healthcare Infrastructure Drive the Dominance of North America in The Viscosupplementation Market?

The high prevalence of osteoarthritis and advanced healthcare infrastructure will drive the dominance of North America in the Viscosupplementation Market. With a significant aging population, the demand for effective pain management solutions is increasing. Moreover, the region's robust healthcare system supports innovation and adoption of new treatments, allowing for better patient outcomes. The presence of leading manufacturers and strong research initiatives further enhances North America's position as a key player in this market.

Will Rising Awareness of Osteoarthritis Treatments Drive the Rapid Growth of The Asia-Pacific Region in The Viscosupplementation Market?

Increasing healthcare expenditures and rising awareness of osteoarthritis treatments will drive the rapid growth of the Asia-Pacific region in the viscosupplementation market. As more individuals become aware of effective pain management options, demand for these therapies is expected to rise. Improved healthcare infrastructure facilitates access to innovative treatments, making them more widely available. Additionally, the growing aging population in this region further contributes to the increasing need for viscosupplementation solutions, supporting market expansion.

Competitive Landscape

The viscosupplementation market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the viscosupplementation market include:

Sanofi S.A.

Anika Therapeutics, Inc.

Seikagaku Corporation

Zimmer Biomet Holdings Inc.

Smith & Nephew PLC

Ferring Pharmaceuticals B.V.

Lifecore Biomedical

Fidia Farmaceutici S.p.A.

Bioventus LLC

Johnson & Johnson Services, Inc.

Latest Developments

In September 2024, Sanofi S.A. announced a licensing agreement with RadioMedix and Orano Med for a next-generation radioligand medicine aimed at treating rare cancers, showcasing its commitment to innovative cancer therapies.

In March 2023, Seikagaku Corporation launched Hyalgan G-F 20 in Japan, a new formulation of hyaluronic acid designed for knee osteoarthritis, enhancing its product portfolio in the viscosupplementation market.

In April 2023, Zimmer Biomet Holdings Inc. received FDA 510(k) clearance for their Persona Knee Hyaluronic Acid, which is intended to provide pain relief for patients suffering from knee osteoarthritis, reflecting their focus on advancing treatment options.

In October 2023, Anika Therapeutics, Inc. reported positive results from a Phase 3 study of Qsymia, aimed at alleviating knee osteoarthritis pain, reinforcing its position in the development of effective non-surgical treatments for joint pain.

1 INTRODUCTION OF GLOBAL VISCOSUPPLEMENTATION MARKET

1.1 Introduction of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL VISCOSUPPLEMENTATION MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL VISCOSUPPLEMENTATION MARKET, BY TYPE

5.1 Overview
5.2 Single Injection Viscosupplementation
5.3 Three Injection Viscosupplementation
5.4 Five Injection Viscosupplementation

6 GLOBAL VISCOSUPPLEMENTATION MARKET, BY APPLICATION

6.1 Overview
6.2 Knee Osteoarthritis
6.3 Hip Osteoarthritis
6.4 Shoulder Osteoarthritis

7 GLOBAL VISCOSUPPLEMENTATION MARKET, BY END-USER

7.1 Overview
7.2 Hospitals
7.3 Orthopedic Clinics/ Ambulatory Surgical Centers
7.4 Retail Pharmacies

8 GLOBAL VISCOSUPPLEMENTATION MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East and Africa

9 GLOBAL VISCOSUPPLEMENTATION MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Sanofi
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Anika Therapeutics, Inc.
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Seikagaku Corp.
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Zimmer Biomet
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Smith & Nephew PLC
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Ferring Pharmaceuticals B.V.
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Lifecore Biomedical
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 LG Life Sciences Ltd.
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Fidia Farmaceutici S.p.A
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 F.Hoffmann-La Roche Ltd.
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments